Stock VLG VENTURE LIFE GROUP PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Venture Life Group plc

Equities

VLG

GB00BFPM8908

Delayed London S.E.
Other stock markets
 04:59:48 2024-07-16 am EDT 		5-day change 1st Jan Change
46.82 GBX +0.16% Intraday chart for Venture Life Group plc +1.79% +39.78%
Jun. 04 Venture Life confident in outlook for year; performs in line AN
Apr. 19 Venture Life renews revolving credit facility with Santander and HSBC AN

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's profit outlook over the next few years is a strong asset.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company has a low valuation given the cash flows generated by its activity.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
VENTURE LIFE GROUP PLC Stock Venture Life Group plc
+39.78% 76.88M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+63.05% 856B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.91% 631B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.78% 359B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.52% 325B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.43% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.62% 244B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+4.95% 234B
A+
NOVARTIS AG Stock Novartis AG
+16.27% 226B
B-
AMGEN INC. Stock Amgen Inc.
+14.63% 177B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. VLG Stock
  4. Ratings Venture Life Group plc